

USPTO PATENT FULL-TEXT AND IMAGE DATABASE[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)[Next List](#)[x](#) [Bottom][View Cart](#)

Searching 1976 to present...

Results of Search in 1976 to present db for:





















ACLM/"conservatively substituted": 52 patents.































Hits 1 through 50 out of 52

[Final 2 Hits](#)[Jump To](#)[Refine Search](#)

ACLM/"conservatively substituted"

PAT.
NO. Title

- 1 [6,930,169](#)  [Method of controlling the binding of calmyrin to presenilin](#)
- 2 [6,924,265](#)  [Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases](#)
- 3 [6,923,968](#)  [Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis](#)
- 4 [6,838,433](#)  [IL-6 antagonist peptides](#)
- 5 [6,811,782](#)  [Peptide composition as immunogen for the treatment of allergy](#)
- 6 [6,753,313](#)  [Multimeric ApoA-I agonist compounds](#)
- 7 [6,740,512](#)  [Neutral sphingomyelinase](#)
- 8 [6,734,169](#)  [Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders](#)
- 9 [6,716,816](#)  [Multimeric Apo A-I agonist compounds](#)
- 10 [6,713,280](#)  [Enhancement of peptide cellular uptake](#)
- 11 [6,617,497](#)  [Cytokinin oxidase](#)
- 12 [6,610,828](#)  [Heliothis ecdysone receptor](#)
- 13 [6,602,854](#)  [Branched multimeric Apo A-I agonist compounds](#)
- 14 [6,599,875](#)  [IL-6 antagonist peptides](#)
- 15 [6,596,498](#)  [Bone stimulating factor](#)
- 16 [6,531,579](#)  [Fused polypeptides](#)
- 17 [6,498,019](#)  [Lecithin-cholesterol acyltransferase protein](#)
- 18 [6,376,464](#)  [Lipid complexes of APO A-1 agonist compounds](#)
- 19 [6,365,372](#)  [SNF2 related CBP activator protein \(SRCAP\)](#)
- 20 [6,352,973](#)  [Bone stimulating factor](#)

- 21 [6,329,341](#)  [Method of treating septic shock](#)
 - 22 [6,284,236](#)  [Cytokine that induces apoptosis](#)
 - 23 [6,268,170](#)  [.alpha.-Tocopherol transport protein: compositions and methods](#)
 - 24 [6,232,449](#)  [Persephin and related growth factors](#)
 - 25 [6,191,103](#)  [Methods for enhancing thrombolysis in a mammal](#)
 - 26 [6,166,180](#)  [Chromosome 21 gene marker, compositions and methods using same](#)
 - 27 [6,093,693](#)  [B cell activation](#)
 - 28 [6,046,166](#)  [Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders](#)
 - 29 [6,040,429](#)  [Congenital heart disease proteins and products related thereto](#)
 - 30 [6,037,323](#)  [Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders](#)
 - 31 [6,022,708](#)  [Fused](#)
 - 32 [6,004,925](#)  [Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders](#)
 - 33 [5,981,704](#)  [Kainate-binding, human CNS receptors of the EAA2 family](#)
 - 34 [5,969,099](#)  [Growth factor analogs](#)
 - 35 [5,955,595](#)  [Cell death regulators](#)
 - 36 [5,888,796](#)  [Clone of a nucleotide sequence encoding a protein having two functions](#)
 - 37 [5,885,820](#)  [Clone of a nucleotide sequence encoding a protein having two functions](#)
 - 38 [5,855,889](#)  [Mammaglobin, a mammary-specific breast cancer protein](#)
 - 39 [5,843,914](#)  [Neurturin and related growth factors](#)
 - 40 [5,837,499](#)  [DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same](#)
 - 41 [5,834,209](#)  [Bcl-x/bcl-2 associated cell death regulator](#)
 - 42 [5,817,622](#)  [Method for providing trophic support for neurons comprising administering neurturin](#)
 - 43 [5,807,824](#)  [C5A receptor antagonists having substantially no agonist activity](#)
 - 44 [5,786,327](#)  [Bone stimulating factor, methods of isolating same, and methods of increasing bone growth comprising administering same](#)
 - 45 [5,763,223](#)  [DNA encoding a cytokine that induces apoptosis](#)
 - 46 [5,747,655](#)  [Neurturin and related growth factors](#)
 - 47 [5,739,307](#)  [Polynucleotide encoding neurturin neurotrophic factor](#)
 - 48 [5,578,569](#)  [Method of increasing bone growth](#)
 - 49 [5,434,073](#)  [Fibrinolytic and anti-thrombotic cleavable dimers](#)
 - 50 [5,286,487](#)  [Covalent angiogenin/RNase hybrids](#)
-

	Next List	Top	View Cart	
Home	Quick	Advanced	Pat Num	Help